Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.
最新股票文章
英伟达股票预测：第三方价格目标
自2025年年初以来，截至4月中旬，英伟达（NVDA）股价下跌约27.37%，但同比上涨26.48%。基于4月22日开盘价98.78美元，自1月初以来，英伟达股票波动显著，受到行业特定因素以及围绕美国贸易关税的更广泛股市不确定性影响。
17:42, 19 五月 2025
评分与评论
评分与评论
